### Claims-to-Experiments Mapping
- Claim 1 (Model generates self-consistent interactions): Supported by unconditional joint generation evaluation (Fig. 3).
- Claim 2 (Model can be conditioned to generate specific interaction profiles): Supported by inpainting evaluation on GDB17 targets.
- Claim 3 (Applicability to drug design): Supported by natural product hopping, hit diversification, and fragment merging experiments.

### Baseline Assessment
- The baselines for natural product ligand hopping include REINVENT and a 10K virtual screen. The REINVENT baseline is strong and appropriately handled (though convergence could arguably be pushed further, the authors state it reached 10,000 oracle calls and took days).
- In the hit diversification task, the baseline is a 10K virtual screen from MOSES-aq. While useful, a more direct comparison to other structure-based generative methods (like Pocket2Mol or DiffSBDD) in the main text would have been stronger. The authors do provide these SBDD comparisons in the Appendix (A.12), which bolsters the rigor significantly.

### Dataset Assessment
The datasets (ShEPhERD-GDB17 and ShEPhERD-MOSES-aq) are appropriate. Using xTB in implicit water to obtain accurate partial charges for ESP surfaces is a highly rigorous choice compared to using cheaper, less accurate MMFF94 charges.

### Metric Assessment
- Uses custom 3D similarity scoring functions which are well-defined.
- Uses AutoDock Vina for the hit diversification task. Vina is a standard but flawed proxy for bioactivity. The authors explicitly acknowledge it as a "weak surrogate."

### Statistical Rigor
The authors generate a substantial number of samples (e.g., 2500 per natural product, 500 per PDB ligand) and report full distributions rather than just top-1 results, avoiding cherry-picking. They correctly report heavy-atom RMSD upon relaxation.

### Ablation Assessment
There is no explicit ablation of the individual model components (e.g., what if you only diffuse ESP and not pharmacophores?), but they do evaluate different model variants (P(x1, x2), P(x1, x3), P(x1, x4)). 

### Missing Experiments
None critically missing. The appendix contains the necessary comparisons against SQUID, DiffSBDD, and SBDD methods. 

### Error Analysis Assessment
The authors provide an honest error analysis regarding validity dropping for larger molecules in pharmacophore generation and the symmetry-breaking issues in unconditional generation.

### Overall Experimental Rigor Verdict
Mostly rigorous with gaps (the main gap being the reliance on Vina for bioactivity proxy, though standard).
